Imugene Limited (IUGNF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Imugene Limited (IUGNF) with AI Score 41/100 (Weak). Imugene Limited is a clinical-stage immuno-oncology company based in Australia, focusing on developing immunotherapies to activate the immune system to fight cancer. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 15, 2026Imugene Limited (IUGNF) Healthcare & Pipeline Overview
Imugene Limited is an Australian clinical-stage immuno-oncology company specializing in the development of cancer immunotherapies, particularly vaccines like HER-Vaxx targeting HER2-positive cancers. With ongoing clinical trials and strategic collaborations, Imugene aims to harness the immune system to eradicate tumors, positioning itself in the competitive biotechnology landscape.
Investment Thesis
Imugene Limited presents a high-risk, high-reward investment opportunity within the immuno-oncology sector. The company's valuation is approximately $70 million, with a negative P/E ratio of -0.92, reflecting its current lack of profitability as a clinical-stage company. The primary value driver is the successful development and commercialization of its lead product, HER-Vaxx, currently in Phase 1b/2 trials. Positive clinical trial data could serve as a significant catalyst, potentially leading to partnerships or acquisition. Key risks include clinical trial failures, regulatory hurdles, and the need for additional funding, given the company's negative profit margin of -1864.1%. The company's high beta of 2.48 indicates significant volatility relative to the market.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.07 billion reflects its position as a small-cap biotechnology company.
- Negative P/E ratio of -0.92 indicates the company is currently not profitable, typical for clinical-stage biotechs.
- Gross margin of -65.9% highlights the high cost of research and development relative to current revenue streams.
- Beta of 2.48 suggests the stock is significantly more volatile than the overall market.
- No dividend yield reflects the company's focus on reinvesting earnings into research and development.
Competitors & Peers
Strengths
- Proprietary immunotherapy technologies.
- Strategic collaborations with leading institutions.
- Experienced management team in immuno-oncology.
- Strong patent portfolio.
Weaknesses
- Limited financial resources as a clinical-stage company.
- Dependence on successful clinical trial outcomes.
- High cash burn rate.
- Negative profit margin.
Catalysts
- Upcoming: Data readout from the Phase 1b/2 clinical trial of HER-Vaxx in gastric cancer (expected in the next 12-24 months).
- Upcoming: Initiation of clinical trials for PD1-Vaxx (expected within the next 2-3 years).
- Ongoing: Progress in strategic collaborations with Celularity Inc. and Eureka Therapeutics, Inc.
- Ongoing: Advancement of the CF33 oncolytic virus platform through preclinical and early clinical studies.
- Ongoing: Identification and validation of new cancer targets for immunotherapy development.
Risks
- Potential: Clinical trial failures for HER-Vaxx, PD1-Vaxx, or CF33.
- Potential: Regulatory hurdles and delays in obtaining marketing approvals.
- Ongoing: Competition from larger pharmaceutical companies with greater resources.
- Ongoing: Need for additional funding and potential dilution of existing shareholders.
- Ongoing: Dependence on key personnel and strategic collaborations.
Growth Opportunities
- HER-Vaxx Clinical Development: The successful completion of Phase 1b/2 trials for HER-Vaxx in gastric cancer represents a significant growth opportunity. Positive data could lead to accelerated development, potential partnerships, and eventual commercialization. The gastric cancer market is substantial, with a global market size projected to reach $4.1 billion by 2027. Timeline: Ongoing clinical trials with data readouts expected in the next 12-24 months.
- PD1-Vaxx Development: Advancing PD1-Vaxx, a cancer vaccine targeting the PD-1 pathway, offers a significant growth avenue. Blocking PD-1 signaling is a validated approach in immuno-oncology, and a successful vaccine could address a broad range of cancers. The market for PD-1/PD-L1 inhibitors is substantial, exceeding $25 billion annually. Timeline: Preclinical and early-stage clinical development over the next 2-3 years.
- CF33 Oncolytic Virus Platform: The CF33 oncolytic virus platform has the potential to be a versatile therapeutic approach for various cancers. Oncolytic viruses are gaining traction as a promising modality in immuno-oncology. The global oncolytic virus therapy market is projected to reach $749 million by 2027. Timeline: Ongoing preclinical and early clinical studies.
- Strategic Collaborations: Leveraging strategic collaborations, such as the partnership with Celularity Inc., to develop combination therapies can accelerate pipeline development and expand therapeutic applications. Combining Imugene's oncolytic virus technology with Celularity's CAR-T cell therapy could create synergistic effects in treating solid tumors. Timeline: Ongoing research and development efforts with potential clinical trials in the next 1-2 years.
- Expansion into New Cancer Targets: Expanding the pipeline to include new cancer targets beyond HER2 and PD-1 can broaden Imugene's market opportunity and reduce reliance on specific therapeutic areas. Identifying novel targets and developing corresponding immunotherapies could drive long-term growth. Timeline: Ongoing research and development efforts to identify and validate new cancer targets.
Opportunities
- Successful completion of clinical trials for HER-Vaxx and PD1-Vaxx.
- Expansion into new cancer targets and therapeutic areas.
- Out-licensing or partnering with larger pharmaceutical companies.
- Growing demand for immuno-oncology therapies.
Threats
- Clinical trial failures.
- Regulatory hurdles and delays.
- Competition from larger pharmaceutical companies.
- Need for additional funding and potential dilution.
Competitive Advantages
- Proprietary immunotherapy technologies, including HER-Vaxx, PD1-Vaxx, and CF33.
- Patent protection for its key products and technologies.
- Strategic collaborations with leading research institutions and pharmaceutical companies.
- Expertise in immuno-oncology and cancer vaccine development.
About IUGNF
Imugene Limited, founded in 1986 and headquartered in Sydney, Australia, is a clinical-stage immuno-oncology company focused on developing innovative immunotherapies. The company's primary objective is to activate the immune system of cancer patients, enabling it to recognize and eradicate tumors. Imugene's lead product, HER-Vaxx, is a HER2-positive cancer vaccine designed to stimulate a polyclonal antibody response against HER2/neu receptors, which are commonly overexpressed in gastric and breast cancers. HER-Vaxx is currently undergoing a Phase 1b/2 clinical study for gastric cancer. In addition to HER-Vaxx, Imugene is developing PD1-Vaxx, a cancer vaccine intended to induce the body to produce polyclonal antibodies that block PD-1 signaling, a key immune checkpoint. The company is also working on CF33, a combination of genomic sequences from various vaccinia virus strains engineered to generate a potent oncolytic virus. Imugene has established research collaborations to expand its therapeutic capabilities, including a partnership with Celularity Inc. to combine Imugene's CD19 oncolytic virus technology with Celularity's CyCART-19, a CD19-targeting allogeneic chimeric antigen receptor T-cell therapy, for the treatment of solid tumors. Furthermore, Imugene has a strategic collaboration with Eureka Therapeutics, Inc. to develop novel cancer therapies. Imugene operates primarily in Australia, focusing on early-stage clinical development and strategic partnerships to advance its pipeline.
What They Do
- Develops HER-Vaxx, a HER2-positive cancer vaccine targeting gastric and breast cancer.
- Creates PD1-Vaxx, a cancer vaccine designed to block PD-1 signaling.
- Engineers CF33, an oncolytic virus platform for cancer treatment.
- Conducts Phase 1b/2 clinical trials for HER-Vaxx in gastric cancer.
- Collaborates with Celularity Inc. to develop combination therapies for solid tumors.
- Partners with Eureka Therapeutics, Inc. to develop novel cancer therapies.
- Focuses on activating the immune system to eradicate tumors.
Business Model
- Develops and patents novel cancer immunotherapies.
- Conducts preclinical and clinical trials to evaluate the safety and efficacy of its products.
- Seeks strategic collaborations and partnerships to accelerate development and commercialization.
- Out-licenses or sells its technologies to larger pharmaceutical companies.
Industry Context
Imugene operates within the competitive immuno-oncology market, a rapidly growing segment of the biotechnology industry. The global immuno-oncology market is projected to reach billions of dollars by 2030, driven by increasing cancer prevalence and advancements in immunotherapy approaches. Key trends include the development of personalized cancer vaccines, oncolytic viruses, and combination therapies. Imugene's focus on HER2-positive cancers and strategic collaborations positions it to potentially capitalize on these trends, although it faces competition from larger, more established pharmaceutical companies.
Key Customers
- Cancer patients participating in clinical trials.
- Hospitals and medical centers conducting clinical trials.
- Pharmaceutical companies seeking to license or acquire Imugene's technologies.
- Research institutions collaborating on immunotherapy development.
Financials
Chart & Info
Imugene Limited (IUGNF) stock price: Price data unavailable
Latest News
No recent news available for IUGNF.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for IUGNF.
Price Targets
Wall Street price target analysis for IUGNF.
MoonshotScore
What does this score mean?
The MoonshotScore rates IUGNF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Leslie Chong
CEO
Leslie Chong serves as the CEO of Imugene Limited, bringing extensive experience in the biopharmaceutical industry. Prior to joining Imugene, she held various leadership roles at Genentech, where she focused on oncology drug development and commercialization. Her background includes a strong understanding of clinical trials, regulatory affairs, and market access. She has a proven track record of driving strategic initiatives and building successful teams.
Track Record: Under Leslie Chong's leadership, Imugene has advanced its clinical pipeline, including the progression of HER-Vaxx into Phase 1b/2 trials. She has also secured strategic collaborations with Celularity Inc. and Eureka Therapeutics, Inc., expanding the company's therapeutic capabilities. Her focus on innovation and strategic partnerships has positioned Imugene for future growth.
IUGNF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Imugene Limited may not meet the minimum financial or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited reporting requirements and may not be subject to the same level of scrutiny as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries significant risks due to the potential for limited information and liquidity.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Higher risk of fraud or manipulation.
- Lower liquidity and wider bid-ask spreads.
- Potential for delisting or trading suspensions.
- Limited regulatory oversight.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's cash flow and financial stability.
- Review any legal or regulatory issues facing the company.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Established research collaborations with reputable institutions.
- Experienced management team with a background in the biopharmaceutical industry.
- Proprietary immunotherapy technologies and patent protection.
- Ongoing clinical trials for its lead product candidates.
- Publicly available information and press releases.
Imugene Limited Stock: Key Questions Answered
What does Imugene Limited do?
Imugene Limited is a clinical-stage immuno-oncology company focused on developing a range of immunotherapies designed to activate the immune system to fight cancer. Their lead product, HER-Vaxx, is a HER2-positive cancer vaccine currently in Phase 1b/2 clinical trials for gastric cancer. The company also develops PD1-Vaxx, a cancer vaccine targeting the PD-1 pathway, and CF33, an oncolytic virus platform. Imugene collaborates with other companies to develop combination therapies, aiming to provide innovative solutions for cancer treatment.
What do analysts say about IUGNF stock?
As of March 15, 2026, there is no readily available analyst consensus on IUGNF stock due to its OTC listing and small market capitalization. Investors should conduct their own due diligence and consider the company's clinical trial progress, financial stability, and competitive landscape. Key valuation metrics include market capitalization and cash burn rate. Growth considerations include the successful development and commercialization of its lead product candidates.
What are the main risks for IUGNF?
The main risks for Imugene Limited include the potential for clinical trial failures, regulatory hurdles, and competition from larger pharmaceutical companies. As a clinical-stage company, Imugene is heavily reliant on the successful development of its product candidates. The company also faces the risk of needing additional funding, which could dilute existing shareholders. Investing in IUGNF carries significant risks due to its OTC listing and small market capitalization.
What are the key factors to evaluate for IUGNF?
Imugene Limited (IUGNF) currently holds an AI score of 41/100, indicating low score. Key strength: Proprietary immunotherapy technologies.. Primary risk to monitor: Potential: Clinical trial failures for HER-Vaxx, PD1-Vaxx, or CF33.. This is not financial advice.
How frequently does IUGNF data refresh on this page?
IUGNF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven IUGNF's recent stock price performance?
Recent price movement in Imugene Limited (IUGNF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary immunotherapy technologies.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider IUGNF overvalued or undervalued right now?
Determining whether Imugene Limited (IUGNF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying IUGNF?
Before investing in Imugene Limited (IUGNF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- OTC market data may be limited or inconsistent.
- Analyst consensus may not be available for OTC stocks.